Total Payments
$416,696
2024 Payments
$61,444
Companies
23
Transactions
338
Medicare Patients
1,760
Medicare Billing
$213,303
Payment Breakdown by Category
Consulting$280,893 (67.4%)
Other$58,275 (14.0%)
Research$40,410 (9.7%)
Travel$30,016 (7.2%)
Food & Beverage$6,436 (1.5%)
Education$665.51 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $280,893 | 70 | 67.4% |
| Unspecified | $40,410 | 31 | 9.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $37,645 | 32 | 9.0% |
| Travel and Lodging | $30,016 | 81 | 7.2% |
| Honoraria | $20,630 | 6 | 5.0% |
| Food and Beverage | $6,436 | 115 | 1.5% |
| Education | $665.51 | 3 | 0.2% |
Payments by Type
General
$376,286
307 transactions
Research
$40,410
31 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $103,684 | 72 | $0 (2024) |
| Janssen Biotech, Inc. | $47,068 | 52 | $0 (2024) |
| Eli Lilly and Company | $41,600 | 7 | $0 (2024) |
| ABBVIE INC. | $40,273 | 35 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $40,045 | 38 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $28,889 | 33 | $0 (2019) |
| Celgene Corporation | $18,223 | 18 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16,416 | 19 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $14,804 | 10 | $0 (2023) |
| Ferring Pharmaceuticals Inc. | $9,530 | 13 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $61,444 | 49 | Janssen Scientific Affairs, LLC ($26,774) |
| 2023 | $66,452 | 54 | Eli Lilly and Company ($15,550) |
| 2022 | $19,259 | 17 | PFIZER INC. ($10,900) |
| 2021 | $71,960 | 31 | ABBVIE INC. ($27,234) |
| 2020 | $39,872 | 19 | PFIZER INC. ($17,370) |
| 2019 | $74,843 | 75 | Takeda Pharmaceuticals U.S.A., Inc. ($20,691) |
| 2018 | $49,742 | 57 | PFIZER INC. ($20,075) |
| 2017 | $33,125 | 36 | Takeda Pharmaceuticals U.S.A., Inc. ($8,198) |
All Payment Transactions
338 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 11/12/2024 | Eli Lilly and Company | OMVOH (Drug) | Consulting Fee | Cash or cash equivalent | $5,400.00 | General |
| Category: Immunology | ||||||
| 07/01/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ETRASIMOD CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 06/04/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Honoraria | Cash or cash equivalent | $2,800.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/24/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,550.00 | General |
| Category: Immunology | ||||||
| 05/19/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Travel and Lodging | In-kind items and services | $381.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/19/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Travel and Lodging | In-kind items and services | $270.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/19/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Travel and Lodging | In-kind items and services | $247.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/19/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/19/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Travel and Lodging | In-kind items and services | $25.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $395.38 | General |
| Category: Immunology | ||||||
| 05/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $146.28 | General |
| Category: Immunology | ||||||
| 05/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Immunology | ||||||
| 04/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $9,375.00 | General |
| 04/09/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| 03/29/2024 | PFIZER INC. | RETACRIT (Biological) | — | In-kind items and services | $1,400.00 | Research |
| Study: ADALIMUMAB PFIZER EPOETIN ZETA INFLIXIMAB HOSPIRA INFLIXIMAB PFIZER PRINABEREL MULTI PRODUCT CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 03/15/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | — | Food and Beverage | In-kind items and services | $42.49 | General |
| 03/15/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | — | Food and Beverage | In-kind items and services | $29.75 | General |
| 03/15/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | — | Food and Beverage | In-kind items and services | $24.76 | General |
| 03/15/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | — | Food and Beverage | In-kind items and services | $21.16 | General |
| 03/15/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | — | Food and Beverage | In-kind items and services | $12.74 | General |
| 03/14/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | — | Travel and Lodging | In-kind items and services | $845.20 | General |
| 03/14/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | — | Travel and Lodging | In-kind items and services | $292.67 | General |
| 03/14/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | — | Food and Beverage | In-kind items and services | $65.25 | General |
| 03/14/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | — | Travel and Lodging | In-kind items and services | $48.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $26,690 | 19 |
| ETRASIMOD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| TOFACITINIB IBD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,280 | 4 |
| ADALIMUMAB PFIZER CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| ADALIMUMAB PFIZER EPOETIN ZETA INFLIXIMAB HOSPIRA INFLIXIMAB PFIZER PRINABEREL MULTI PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,400 | 1 |
| A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohns Disease | UCB, Inc. | $420.00 | 1 |
| Non-Melanoma Skin Cancer: Incidence and Potential Risk Factors in Crohns Disease Patients in the SECURE Registry | UCB, Inc. | $400.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 463 | 525 | $358,760 | $58,127 |
| 2022 | 9 | 412 | 471 | $314,631 | $51,435 |
| 2021 | 10 | 459 | 521 | $341,982 | $59,324 |
| 2020 | 9 | 426 | 460 | $290,504 | $44,417 |
Total Patients
1,760
Total Services
1,977
Medicare Billing
$213,303
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 126 | 127 | $189,484 | $20,393 | 10.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 153 | 177 | $46,976 | $18,941 | 40.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 57 | 59 | $64,133 | $4,526 | 7.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 21 | 21 | $26,229 | $3,445 | 13.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 43 | 43 | $7,431 | $3,365 | 45.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 21 | 21 | $9,317 | $3,009 | 32.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 39 | $8,112 | $2,562 | 31.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $4,378 | $1,190 | 27.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 13 | 27 | $2,700 | $697.19 | 25.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 141 | 171 | $37,890 | $18,342 | 48.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 108 | 109 | $162,628 | $17,076 | 10.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 52 | 54 | $58,698 | $4,173 | 7.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 41 | 48 | $6,720 | $3,734 | 55.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 15 | 15 | $18,735 | $2,499 | 13.3% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 16 | 16 | $19,984 | $2,036 | 10.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $4,615 | $1,721 | 37.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 21 | $2,961 | $1,237 | 41.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 15 | 24 | $2,400 | $615.12 | 25.6% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 111 | 112 | $167,104 | $17,955 | 10.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 81 | 88 | $19,360 | $10,768 | 55.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 90 | 110 | $15,530 | $8,290 | 53.4% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 66 | 67 | $72,829 | $5,533 | 7.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 43 | $7,928 | $3,752 | 47.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 22 | 22 | $7,150 | $3,724 | 52.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 17 | 17 | $21,233 | $3,407 | 16.0% |
About Dr. Gary Lichtenstein, MD
Dr. Gary Lichtenstein, MD is a Gastroenterology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700890720.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Lichtenstein, MD has received a total of $416,696 in payments from pharmaceutical and medical device companies, with $61,444 received in 2024. These payments were reported across 338 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($280,893).
As a Medicare-enrolled provider, Lichtenstein has provided services to 1,760 Medicare beneficiaries, totaling 1,977 services with total Medicare billing of $213,303. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Internal Medicine
- Location Philadelphia, PA
- Active Since 07/27/2006
- Last Updated 09/16/2019
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1700890720
Products in Payments
- XELJANZ (Drug) $77,055
- STELARA (Biological) $66,436
- Entyvio (Biological) $35,345
- TREMFYA (Drug) $16,368
- Cimzia (Drug) $10,150
- ZEPOSIA (Drug) $10,071
- NASCOBAL (Drug) $9,045
- VELSIPITY (Drug) $7,670
- ZYMFENTRA (Biological) $6,723
- CLENPIQ (Drug) $6,271
- SIMPONI (Biological) $6,221
- Otezla (Drug) $6,149
- Humira (Biological) $5,933
- XIFAXAN (Drug) $5,659
- REMICADE (Biological) $5,444
- OMVOH (Drug) $5,400
- Ozanimod (Drug) $4,387
- PREPOPIK (Drug) $3,259
- ABRILADA (Biological) $3,200
- GED-0301 (Drug) $2,976
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Philadelphia
Xiaoli Ma, Md, MD
Gastroenterology — Payments: $717,441
Gastroenterology $717,441
Dr. Neilanjan Nandi, Md, MD
Gastroenterology — Payments: $334,815
Gastroenterology $334,815
Dr. David Lichtenstein, M.d, M.D
Gastroenterology — Payments: $263,694
Gastroenterology $263,694
James Lewis, Md, MD
Gastroenterology — Payments: $229,188
Gastroenterology $229,188
Mark Osterman, Md, MD
Gastroenterology — Payments: $142,430
Gastroenterology $142,430
Dr. Oleg Volchonok, M.d, M.D
Gastroenterology — Payments: $116,291
Gastroenterology $116,291